Max Robotics — Global Service Robot Directory + US Certification

About

JH Fregnani is a distinguished surgical oncologist whose research has significantly advanced the management of gynecologic cancers, particularly cervical cancer. His key research areas include conservative surgical approaches for early-stage disease, aiming to reduce treatment morbidity without compromising oncologic outcomes. Fregnani's most notable contribution is the "23 Concerv" prospective trial, which evaluated conservative surgery for low-risk early-stage cervical cancer. This landmark study, published in 2019 with 15 citations, demonstrated that less radical procedures can be safely performed in carefully selected patients, challenging traditional radical hysterectomy paradigms and offering women fertility-sparing options. Beyond this trial, his work has influenced clinical guidelines for cervical cancer treatment, emphasizing personalized, risk-adapted strategies. Fregnani's research has been instrumental in shifting the field toward de-escalation of therapy, reducing overtreatment while maintaining survival rates. His contributions have been recognized internationally, and he continues to shape the future of gynecologic oncology through collaborative trials and mentorship. With a career dedicated to improving patient outcomes through evidence-based surgical innovation, Fregnani remains a pivotal figure in the fight against cervical cancer.